Creating a paradigm shift in raw materials
Synthetic biology based on natural genomic knowledge has wide-ranging potential to advance how we bring more effective and safer therapeutics to patients. It allows us to treat more patients by speeding production and lowering cost.
Synthetic DNA does not require larger fermentation volumes of plasmids. This means we can generate DNA with no bacterial impact that can be produced in higher volumes in significantly less time than plasmid DNA. More importantly, we can assemble safer DNA sequences at a larger scale with the same therapeutic effect of natural synthesized DNA.
Working collaboratively with our partner Touchlight Genetics, Ltd., we are advancing Doggybone™ DNA (dbDNA™) into clinical applications with extensive development and manufacturing capabilities.